FederationDecentralized Coordinationmedium
Patient-Owned Retinal Outcomes Network
A federated registry for retinal imaging, treatment intervals, adverse events, and visual-acuity outcomes could let clinics and patients compare anti-VEGF performance across branded drugs, biosimilars, and dosing strategies without surrendering all data to one manufacturer or payer.
Thesis
The market structure shifts modestly from manufacturer-controlled evidence and payer claims toward patient- and clinic-governed real-world evidence that can support lower-cost alternatives and more transparent treatment protocols.
Bitcoin / decentralization role
Decentralization matters through federated data custody and multi-party governance, not through Bitcoin payments. Patients, retina clinics, and researchers can coordinate evidence while keeping identifiable health data local or permissioned.
Coordination mechanism
Participating clinics submit standardized outcome records and imaging-derived metrics to interoperable registries; patient organizations and academic validators define schemas, consent flows, and publication rules.
Verification / trust model
Records are tied to clinic attestations, audit logs, consent receipts, and reproducible analytics pipelines. Fraud is constrained by cross-checking imaging metadata, treatment dates, adverse-event reports, and clinic-level outlier analysis, though medical data privacy limits full public verification.
Failure modes
- • Clinics may resist workflow burden or fear payer and legal exposure.
- • Outcome data can be confounded by patient severity, adherence, and imaging-device differences.
- • Manufacturers or payers could capture governance unless patient and academic representation is strong.
Adoption path
- • Start with retina practices and patient groups that already collect OCT and injection-interval data.
- • Publish open outcome schemas and de-identified benchmark reports comparing real-world durability, safety, and access barriers.
- • Use the evidence base to support biosimilar adoption, better payer policies, and independent protocol research.
Decentralization fit
6.0/10
Federated patient and clinic data can decentralize evidence generation, but therapy delivery remains centralized and regulated.
Coordination credibility
5.0/10
Retina clinics already collect relevant imaging and injection data, but incentives for standardized sharing are uneven.
Implementation feasibility
5.0/10
Open biomedical data platforms make the technical layer plausible; privacy, consent, clinical workflow integration, and governance are the hard parts.
Incumbent pressure
4.0/10
Better real-world evidence can pressure pricing and switching behavior, but it does not eliminate regulatory approval, manufacturing, or physician trust barriers.